Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
DN002
- Development stage
- Phase 1
- Lead developer
- Suzhou Deneugen Biotechnology
- Modality
- Recombinant Proteins and Enzymes
- Administration
- Intramuscular
01
Overview
DN002 is a recombinant botulinum toxin type A2 (recombinant A2-type botulinum toxin) being developed by Suzhou Deneugen Biotechnology for the treatment of cervical dystonia. As a neurotoxin, it acts by binding to synaptic vesicle glycoprotein 2 (SV2) receptors on presynaptic nerve terminals, followed by internalization and subsequent cleavage of synaptosomal-associated protein 25 (SNAP-25). This cleavage prevents the assembly of the SNARE complex and inhibits the release of acetylcholine at the neuromuscular junction, leading to localized muscle relaxation. DN002 is currently in Phase I clinical development in China.
02
Targets
SV2A (Synaptic vesicle glycoprotein 2A)SV2B (Synaptic vesicle glycoprotein 2B)SV2C (Synaptic vesicle glycoprotein 2C)SNAP25 (Synaptosome-associated protein 25)
Beyond the preview
Go deeper on DN002.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on DN002.